Skip to main content
. Author manuscript; available in PMC: 2020 Dec 29.
Published in final edited form as: Nat Immunol. 2020 Jun 29;21(8):857–867. doi: 10.1038/s41590-020-0705-6

Figure 6. FMF mutations are associated with increased Y. pestis-induced IL-1β release from human myeloid cell lines and PBMCs.

Figure 6

a, b, IL-1β measurements of culture supernatants of retroviral transduced U937 cells, expressing WT or indicated mutant pyrin proteins, differentiated with PMA and infected with indicated MOI of WT (a) or ΔyopM (b) Y. pestis strains. Results are presented as mean ± s.e.m., for n=5 independent biological replicates. *P = 0.0159 and **P = 0.0079 (unpaired two-tailed t test) compared to WT. c, IL-1β measurements of culture supernatants of PBMCs from healthy controls (n=11), FMF patients (n=8) with homozygous or compound heterozygous common FMF mutations (MEFV_p.M680I, MEFV_p.M694V, or MEFV_p.V726A) or HIDS patients (n=6) infected with indicated MOI of Y. pestis. **P = 0.0036 and ***P = 0.0012 (unpaired two-tailed t test) d, IL-1β measurements of culture supernatants of PBMCs from healthy controls (n=11) or FMF patients (n=8) with homozygous or compound heterozygous common FMF mutations (MEFV_p.M680I, MEFV_p.M694V, or MEFV_p.V726A) infected with indicated MOI of ΔyopM Y. pestis. e, IL-1β measurements of culture supernatants of PBMCs from healthy controls (n=7) or FMF patients (n=8) infected with indicated MOI of Burkholderia cenocepacia. f, IL-1β measurements of culture supernatants of CD14+ monocytes from healthy controls (n=28) or asymptomatic FMF carriers (HT, n=34) with one of the FMF mutations (MEFV_p.M680I, MEFV_p.M694V, or MEFV_p.V726A) infected with indicated MOI of Y. pestis. Each symbol represents an individual person; small horizontal lines indicate the mean (c–f). *P = 0.0141 and **P = 0.009 (unpaired two-tailed t test).